WallStreetZen

NASDAQ: NVAX
Novavax Inc Earnings & Revenue

NVAX past revenue growth

How has NVAX's revenue growth performed historically?
Company
4,991.93%
Industry
606.32%
Market
28.71%
NVAX's revenue has grown slower (97.51% per year) than the US Biotechnology industry average (120.44%)
Performance
NVAX's revenue has grown faster (97.51% per year) than the US market average (16.77%)
Performance
NVAX's revenue growth is accelerating - its growth over the last year (4,991.93%) is above its 5-year compound annual rate (97.51%)
Performance

NVAX earnings and revenue history

Current Revenue
$919.5M
Current Earnings
-$615.1M
Current Profit Margin
-66.9%

NVAX Return on equity

Current Company
-125.7%
Current Industry
-34.6%
Current Market
31.1%
NVAX's Return on Equity (-125.7%) shows a company that is not efficient at transforming shareholder equity into returns
Performance

NVAX Return on assets

Current Company
-40.6%
Current Industry
-9.2%
Current Market
6.5%
NVAX is generating lower Return on Assets (-40.6%) than the US Biotechnology industry average (-8.58%)
Performance

NVAX Return on capital employed

Current Company
-42.54%
Current Industry
4.4%
NVAX has gotten more efficient at generating Return on Capital (-42.54%) compared to 3 years ago (-74.54%)
Performance

NVAX earnings dates

Next earnings date
Aug 9, 2021

Novavax Earnings & Revenue FAQ

What were NVAX's earnings last quarter?

On May 10, 2021, Novavax (NASDAQ: NVAX) reported Q1 2021 earnings per share (EPS) of -$3.05, up 425.86% year over year. Total Novavax earnings for the quarter were -$222.72 million. In the same quarter last year, Novavax's earnings per share (EPS) was -$0.58.

What was NVAX's earnings growth in the past year?

As of Q2 2021, Novavax's earnings has grown null year over year. Novavax's earnings in the past year totalled -$615.11 million.

What is NVAX's earnings date?

Novavax's earnings date is Aug 09, 2021. Add NVAX to your watchlist to be reminded of NVAX's next earnings announcement.

What was NVAX's revenue last quarter?

On May 10, 2021, Novavax (NASDAQ: NVAX) reported Q1 2021 revenue of $447.23 million up 13,143.38% year over year. In the same quarter last year, Novavax's revenue was $3.38 million.

What was NVAX's revenue growth in the past year?

As of Q2 2021, Novavax's revenue has grown 4,991.93% year over year. This is 4,385.61 percentage points higher than the US Biotechnology industry revenue growth rate of 606.32%. Novavax's revenue in the past year totalled $919.45 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.